文献速递临床试验与 GCP流行病学与生物统计

泼尼松龙与秋水仙碱治疗基层医疗急性痛风比较:实用、多中心、随机、双盲COPAGO非劣效试验的统计分析计划

Prednisolone Versus Colchicine for Acute Gout in Primary Care: statistical analysis plan for the pragmatic, multicenter, randomized, and double-blinded COPAGO non-inferiority trial.
PubMed 文献 · Trials · 2024-04-03

本研究为实用、前瞻性、双盲、双模拟、平行组、随机非劣效试验,比较泼尼松龙与秋水仙碱治疗基层急性痛风患者的疗效。计划在3所大学医学中心周边60家诊所招募314例患者,以第3天疼痛绝对水平(NRS 0-10)为主要结局,泼尼松龙组30 mg用5天,秋水仙碱组第1天1.5 mg、第2-5天1 mg。

要点

  • 计划招募314例急性痛风患者,按1:1随机分组,以90%把握度检验泼尼松龙相对秋水仙碱的非劣效性。
  • 主要结局为第3天最后24小时疼痛绝对水平(NRS 0-10),非劣效界值为1个单位。
  • 次要结局包括平均治疗反应、关节肿胀与压痛、关节躯体功能及患者整体治疗成功评估。

核心结论

  • 该试验将直接比较秋水仙碱与泼尼松龙在基层急性痛风患者中减轻疼痛的疗效,并提示可能的安全性信号。

研究设计与样本

  • 实用、前瞻性、双盲、双模拟、平行组、随机非劣效试验,比较泼尼松龙与秋水仙碱治疗急性痛风。
  • 计划在3所大学医学中心(Greifswald、Göttingen、Würzburg)周边60家诊所招募共314例患者,以补偿10%脱落。
  • 纳入标准为痛风发作发生在过去2天内的急性痛风患者,患者就诊于全科医生。
  • 采用区组大小为2、4、6的置换区组随机化,按1:1比例分组。

主要发现

  • 干预组接受泼尼松龙30 mg治疗5天,标准治疗组接受低剂量秋水仙碱(第1天1.5 mg;第2-5天1 mg)。
  • 主要结局为第3天最后24小时疼痛绝对水平,采用数值评定量表(NRS 0-10)测量。
  • 使用调整年龄、性别和基线疼痛的多元线性回归模型,若效应估计值包括置信区间低于NRS 1个单位的界值,则认为泼尼松龙非劣效。
  • 次要结局包括平均治疗反应、关节肿胀和压痛、关节躯体功能以及患者对治疗成功的整体评估。
  • 从第0天至第6天,患者每日完成研究日记记录疼痛量化,并评估潜在副作用和收缩压变化。

关键数值与推荐

  • 非劣效界值为NRS 1个单位,泼尼松龙组与秋水仙碱组比较,效应估计值包括置信区间低于该界值即判定非劣效。
  • 计划样本量N=314,检验效能90%,允许10%脱落。
  • 随机化按1:1比例,区组大小为2、4、6。
  • 泼尼松龙剂量为30 mg每日一次共5天;秋水仙碱第1天1.5 mg,第2-5天1 mg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To date, colchicine and prednisolone are two effective therapies for the treatment of acute gout but have never been compared directly in a randomized clinical trial. In addition, in previous trials of treating acute gout patients with concomitant comorbidities were often excluded due to contraindications to naproxen. STUDY DESIGN: This pragmatic, prospective, double-blind, double-dummy, parallel-group, randomized, non-inferiority trial compares prednisolone with colchicine in terms of non-inferiority in patients with acute gout. Patients presenting to their general practitioner with acute gout can be included if the gout attack has occurred within the last 2 days. A total of 60 practices in the vicinity of three university medical centers (Greifswald, Göttingen, and Würzburg) participate in the study. The intervention group receives 30 mg prednisolone for 5 days, while the group of standard care receives low-dose colchicine (day 1: 1.5 mg; days 2-5: 1 mg). The first dose of treatment is provided at day 0 when patients present to the general practitioner due to an acute gout attack. From day 0 to day 6, patients will be asked to complete a study diary on daily basis regarding pain quantification. For safety reasons, potential side effects and the course of systolic blood pressure are also assessed. STATISTICAL ANALYSIS PLAN: N = 314 patients have to be recruited to compensate for 10% of dropout and to allow for showing non-inferiority of prednisolone compared to colchicine with a power of 90%. We use permuted block randomization with block sizes of 2, 4, and 6 to avoid imbalanced treatment arms in this multi-center study; patients are randomized in a 1:1 ratio. The absolute level of pain on day 3 (in the last 24 h) is the primary outcome and measured on a numerical rating scale (NRS: 0-10). Using a multiple linear regression model adjusted for age, sex, and pain at baseline, prednisolone is considered non-inferior if the effect estimate including the confidence intervals is lower than a margin of 1 unit on the NRS. Average response to treatment, joint swelling and tenderness, physical function of the joint, and patients' global assessment of treatment success are secondary outcomes. DISCUSSION: The trial will provide evidence from a direct comparison of colchicine and prednisolone regarding their efficacy of pain reduction in acute gout patients of primary care and to indicate possible safety signals. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05698680 first posted on January 26, 2023 (retrospectively registered).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Richter A, Truthmann J, Hummers E, et al. Prednisolone Versus Colchicine for Acute Gout in Primary Care: statistical analysis plan for the pragmatic, multicenter, randomized, and double-blinded COPAGO non-inferiority trial. Trials. 2024. PMID: 38570873. doi:10.1186/s13063-024-08066-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。